News

People who develop epilepsy after a traumatic brain injury are at an 80% higher risk of premature death compared to those who ...
In a groundbreaking discovery, scientists have found that the birth of new brain cells in adults plays a key role in verbal ...
In The Mind Electric, the neurologist explores the roots of neurological disease and the narratives that shape medicine. You write about a patient who fabricated details about her surroundings ...
“This rare form of seizure is typically associated with abnormal activity in the brain’s frontal lobe, particularly the supplementary motor area, which is responsible for controlling motor function ...
Objective We sought to augment the presurgical workup of medically refractory temporal lobe epilepsy by creating a supervised machine learning technique that uses diffusion-weighted imaging to ...
Neurona Therapeutics has gained $102m to support the advancement of its investigational cell therapy, NRTX-1001, into Phase III testing for drug-resistant mesial temporal lobe epilepsy (MTLE ... The ...
The asset, dubbed NRTX-1001, is currently being tested in an open-label phase 1/2 trial among patients with drug-resistant mesial temporal lobe epilepsy ... in which adults with drug-resistant ...
Mesial temporal lobe epilepsy is the most common form of epilepsy ... designation in June 2024. The trial will enrol adults with drug-resistant MTLE in a randomised, double-blind design, assigning ...
Temporal lobe attention deficit disorder (ADD ... which may allow them to access support. If an adult or child has more serious symptoms, it is important to seek help as soon as possible.
Your awareness may or may not be affected. Symptoms of seizures in the frontal lobes can include: If you have been diagnosed with temporal lobe epilepsy it means you have seizures starting in one or ...
Background Temporal lobe epilepsy (TLE) predisposes individuals to cognitive difficulties and psychosocial consequences. Evaluating its impact on quality of life (QOL) is essential for patient care.